Pharmacogenetics of anti-HIV drugs

被引：54

作者：

Telenti, A. ^{[1
]}

Zanger, U. M. ^{[2
,3
]}

机构：

[1] Univ Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland

[2] Univ Tubingen, D-72074 Tubingen, Germany

[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2008年 / 48卷

关键词：

protease inhibitors; non-nucleoside reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; HIV susceptibility; ADME proteins;

D O I：

10.1146/annurev.pharmtox.48.113006.094753

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.

引用

页码：227 / 256

页数：30

共 161 条

[21] Considering genetic profiles in functional studies of immune responsiveness to HIV-1 [J].

Carrington, M ;

Nelson, G ;

O'Brien, SJ .

IMMUNOLOGY LETTERS, 2001, 79 (1-2) :131-140

[22] Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis [J].

Cohn, JA ;

Friedman, KJ ;

Noone, PG ;

Knowles, MR ;

Silverman, LM ;

Jowell, PS .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (10) :653-658

[23] Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo [J].

Colombo, S ;

Soranzo, N ;

Rotger, M ;

Sprenger, R ;

Bleiber, G ;

Furrer, H ;

Buclin, T ;

Goldstein, D ;

Décosterd, L ;

Telenti, A .

PHARMACOGENETICS AND GENOMICS, 2005, 15 (09) :599-608

[24] MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES [J].

CORDONCARDO, C ;

OBRIEN, JP ;

CASALS, D ;

RITTMANGRAUER, L ;

BIEDLER, JL ;

MELAMED, MR ;

BERTINO, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) :695-698

[25] Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection [J].

Csajka, C ;

Marzolini, C ;

Fattinger, K ;

Décosterd, LA ;

Fellay, J ;

Telenti, A ;

Biollaz, J ;

Buclin, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :20-30

[26] Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6 [J].

Cui, Y ;

König, J ;

Leier, I ;

Buchholz, U ;

Keppler, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9626-9630

[27] Significance of the minor cytochrome P450 3A isoforms [J].

Daly, AK .

CLINICAL PHARMACOKINETICS, 2006, 45 (01) :13-31

[28] Acute pancreatitis in human immunodeficiency virus-infected patients: A review [J].

Dassopoulos, T ;

Ehrenpreis, ED .

AMERICAN JOURNAL OF MEDICINE, 1999, 107 (01) :78-84

[29] Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J].

Dean, M ;

Carrington, M ;

Winkler, C ;

Huttley, GA ;

Smith, MW ;

Allikmets, R ;

Goedert, JJ ;

Buchbinder, SP ;

Vittinghoff, E ;

Gomperts, E ;

Donfield, S ;

Vlahov, D ;

Kaslow, R ;

Saah, A ;

Rinaldo, C ;

Detels, R ;

OBrien, SJ .

SCIENCE, 1996, 273 (5283) :1856-1862

[30] Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro [J].

Desta, Zeruesenay ;

Saussele, Tanja ;

Ward, Bryan ;

Blievernicht, Julia ;

Li, Lang ;

Klein, Kathrin ;

Flockhart, DavidA ;

Zanger, Ulrich M. .

PHARMACOGENOMICS, 2007, 8 (06) :547-558

← 1 2 3 4 5 6 7 8 9 10 →